Fluvoxamine is a small-molecule research product rather than a peptide.
Also known as fluvoxamine
Research shortlist · Sep 12, 2026
No exact product basis had a qualifying vendor in the Sep 12, 2026 research snapshot.
Vendor records are available below, but the Sep 12, 2026 research snapshot did not support a same-product shortlist.
What it is
Fluvoxamine is an oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder. It has a role as an antidepressant, an anxiolytic drug and a serotonin uptake inhibitor. It is a 5-methoxyvalerophenone O-(2-aminoethyl)oxime and a member of (trifluoromethyl)benzenes. It is functionally related to a (trifluoromethyl)benzene. The listed molecular formula is C15H21F3N2O2. PepGrades separately preserves the catalog category because a chemical identity record does not establish a use, outcome, or product quality.
This label describes the available research record, not whether the compound is safe or effective for an individual.
Research context
5 registered studies were found under this name in the current review. Each study still needs to be checked for the exact compound identity, population, endpoints, and results.
Search indexed research for this compound ↗Market context
Fluvoxamine is commonly sold or discussed for a range of compound-specific research goals. That describes market demand, not proof that the compound is safe or effective.
Market demand and online discussion do not establish product quality, safety, or effectiveness.Same format. Same amount.
0 of 0 formats had a qualifying research shortlist on Sep 12, 2026. Vendor counts below reflect the available price observations.
Vendor profiles and catalog information are still available below.
Vendor directory
Grades describe the vendor record overall. They are not a test result for every product.
| Vendor | Grade | Compared offers | In stock when checked | Lowest effective package | Profile |
|---|---|---|---|---|---|
| Next ChemsNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
Sources and review
Last editorial review: Aug 30, 2026. Sources support the compound guide only and do not affect vendor grades.